Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Oncology Research and Treatment Année : 2020

Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx

Fichier non déposé

Dates et versions

hal-02995983 , version 1 (09-11-2020)

Identifiants

  • HAL Id : hal-02995983 , version 1

Citer

L. Thurner, V Poeschel, C. Haioun, R. Houot, P. Gaulard, et al.. Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx. Oncology Research and Treatment, 2020, 43 (SUPPL 4), pp.60-61. ⟨hal-02995983⟩
17 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More